Skip to main content
. 2021 Mar 23;10(2):223–231. doi: 10.1093/toxres/tfab006

Table 3.

comparison of different concentrations of PEBHAE in MN assay

Cyto B (4 μg/ml) for 28 h
Mono N Bi N Multi N MN CBPI RI Cytostasis (%)
NC 400 160 8 12 1/31
Positive control (cisplatin, 10 μM) 612 72 7 135 1/12 46/93 60/99
PEBHAE only (200 μg/ml) 436 116 5 29 1/23 76/74 27/48 (***)
Cisplatin 10 μM +
PEBHAE, 10 μg/ml 460 96 12 97 1/22 63/39 31/97 (**)
PEBHAE, 20 μg/ml 474 96 8 93 1/20 63/16 37/87 (*)
PEBHAE, 50 μg/ml 481 86 9 88 1/18 56/80 42/50
PEBHAE, 75 μg/ml 492 98 8 82 1/20 64/70 37/12 (*)
PEBHAE, 100 μg/ml 486 99 10 65 1/20 65/13 36/81 (**)
PEBHAE, 200 μg/ml 489 93 8 53 1/19 61/62 40/62 (*)

Data are expressed as mean (n = 3). Signs (*), (**), and (***) represent statistically significant difference (P < 0.05, P < 0.01, and P < 0.001, respectively) compared with positive control (i.e. cells that received only cisplatin with a concentration of 10 μM). Cyto B, cytochalasin B; Mono N, mono nucleated cell; Bi N, binucleated cell; Multi N, multi-nucleated cell; CBPI, cytokinesis-block proliferation index; RI, replicative index.